Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
|Articles|April 8, 2011
Supplements and Featured Publications
- Improving Asthma Care: An Update for Managed Care [CME/CPE]
- Volume 17
- Issue 3 Suppl
Improving Asthma Care: An Update for Managed Care
Advertisement
After reading “Improving Asthma Care: An Update for Managed Care,” complete the program evaluation and select the 1 best answer to each of the posttest questions.
A statement of continuing education hours will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher.
Articles in this issue
over 15 years ago
Emerging Therapeutic Options for Asthmaover 15 years ago
Managed Care Opportunities for Improving Asthma Careover 15 years ago
The Burden of Asthma and Improving Patient Outcomesover 15 years ago
Participating Faculty: Improving Asthma CareAdvertisement
Related to this article
Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
OCT patterns help distinguish MS, NMOSD, and MOGAD after optic neuritis, while timing and protocol shape MRI's diagnostic yield, experts say.
Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Advertisement
Advertisement
Trending on AJMC
1
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
2
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
3
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
4
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
5